Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections

被引：391
|
作者：
Steenbergen, JN [1 ]
Alder, J [1 ]
Thorne, GM [1 ]
Tally, FP [1 ]
机构：
[1] Cubist Pharmaceut Inc, Lexington, MA 02421 USA
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2005年 / 55卷 / 03期
关键词：
MRSA; cSSSI; vancomycin;
D O I：
10.1093/jac/dkh546
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
Infections caused by drug-resistant pathogens are on the rise. Daptomycin, a cyclic lipopeptide with activity against most Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus, is a newly US-FDA approved antimicrobial for complicated skin and skin structure infections (cSSSI). Daptomycin has a unique mechanism of action that results in destruction of the membrane potential. The rapid bactericidal activity of daptomycin makes it an attractive antibiotic for serious Gram-positive infections.
引用
收藏
页码：283 / 288
页数：6
相关论文
共 50 条
  • [1] Daptomycin: a rapidly bactericidal lipopeptide for the treatment of Gram-positive infections
    Konafani, Zeina A.
    Corey, G. Ralph
    [J]. EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2007, 5 (02) : 177 - 184
  • [2] Daptomyclin: A novel lipopeptide antibiotic for the treatment of resistant gram-positive infections
    Sun, HK
    Kuti, JL
    Nicolau, DP
    [J]. FORMULARY, 2003, 38 (11) : 634 - +
  • [3] Daptomycin treatment in Gram-positive vascular graft infections
    de las Revillas, Francisco Arnaiz
    Fernandez-Sampedro, Marta
    Maria Arnaiz-Garcia, Ana
    Gutierrez-Cuadra, Manuel
    Arminanzas, Carlos
    Pulitani, Ivana
    Ponton, Alejandro
    Tascon, Valentin
    Garcia, Ivan
    Carmen Farinas, Maria
    [J]. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2018, 68 : 69 - 73
  • [4] Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections
    Eisenstein, BI
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2004, 13 (09) : 1159 - 1169
  • [5] Development of daptomycin for Gram-positive infections
    Tally, FP
    DeBruin, MF
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (04) : 523 - 526
  • [6] Daptomycin as a promising antimicrobial agent for the treatment of serious infections caused by resistant gram-positive organisms
    Tarai, B.
    Das, P.
    Kumar, D.
    [J]. INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2014, 32 (03) : 353 - 354
  • [7] Brazilian experience in EU-CORE: daptomycin registry and treatment of serious Gram-positive infections
    Timerman, Artur
    Brites, Carlos
    Bicudo, Eliana
    Grinbaum, Renato S.
    Filho, Rubens Costa
    Carrilho, Claudia D. M.
    Bichels, Andre
    Barreto, Tania
    [J]. BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, 2013, 17 (06): : 647 - 653
  • [8] Daptomycin for the treatment of gram-positive infections after cardiac surgery
    Luchting, B.
    Weis, F.
    Heyn, J.
    Beiras-Fernandez, A.
    [J]. MEDIZINISCHE KLINIK-INTENSIVMEDIZIN UND NOTFALLMEDIZIN, 2013, 108 (01) : 59 - 62
  • [9] Daptomycin, a new drug class for the treatment of gram-positive infections
    Alder, JD
    [J]. DRUGS OF TODAY, 2005, 41 (02) : 81 - 90
  • [10] FUTURE TRENDS IN THE TREATMENT OF SERIOUS GRAM-POSITIVE INFECTIONS
    Metzger, Rosemarie
    Bonatti, Hugo
    Sawyer, Robert
    [J]. DRUGS OF TODAY, 2009, 45 (01) : 33 - 45
12345